. AQR Capital Management LLC bought a new position in shares of Sorrento Therapeutics during the 1st quarter valued at about $53,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Sorrento Therapeutics by 584.4% during the 1st quarter. JPMorgan Chase & Co. now owns 280,747 shares of the biopharmaceutical company’s stock valued at $517,000 after purchasing an additional 239,729 shares during the last quarter. 16.14% of the stock is owned by institutional investors and hedge funds.